Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (BCAB) is a clinical-stage biopharmaceutical innovator advancing conditionally active biologic therapies for cancer treatment. This news hub provides investors and industry professionals with essential updates on the company’s proprietary CAB technology platform, clinical trial progress, and strategic developments.
Access timely press releases covering key milestones including regulatory filings, partnership announcements, and financial results. Our curated collection features updates on antibody-drug conjugate trials, intellectual property expansions, and operational developments across BioAtla’s global facilities.
This resource serves as your primary source for tracking BCAB’s progress in developing tumor-selective therapies. Bookmark this page for direct access to verified corporate communications and objective reporting on clinical advancements. Check regularly for updates on pipeline candidates and business strategy execution.
BioAtla (Nasdaq: BCAB), a clinical-stage biotech firm specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, announced its participation in the Jefferies Global Healthcare Conference in New York from June 4-6, 2024.
The event will feature a fireside chat and one-on-one investor meetings on June 5, 2024, at 8:00 a.m. ET. The webcast will be available for interested parties.
BioAtla announced promising Phase 1 clinical trial results for evalstotug, a conditionally active anti-CTLA-4 antibody, in combination with nivolumab.
Key findings include prolonged progression-free survival (PFS) of over 10 months in refractory PD1 failure patients, with manageable safety profiles allowing extended treatment durations.
High doses (up to 1 gram) showed positive responses, including complete and partial responses in various carcinomas. The disease control rate was 52%, and several patients remained progression-free for over a year.
BioAtla plans to commence a Phase 3 trial in late 2024 for first-line metastatic BRAF-mutated melanoma, following an anticipated FDA meeting.
BioAtla (Nasdaq: BCAB) announced its Q1 2024 financial results and clinical progress. Key highlights include positive Phase 2 data for ozuriftamab vedotin in SCCHN, with 11 responses and an 86% Disease Control Rate (DCR). Evalstotug's Phase 1 study shows promising safety and efficacy, with upcoming Phase 2 data readouts. Mecbotamab vedotin's Phase 2 trial in UPS is progressing well. BioAtla also reported a cash balance of $80.6 million, projected to fund operations into 2H 2025. Financial results show a reduction in R&D and G&A expenses but a net loss of $23.2 million, lower than last year's $27.5 million. Management will host a conference call to discuss these updates.
BioAtla, Inc. (Nasdaq: BCAB) will be participating in the Citizens JMP Life Sciences Conference in New York on May 13-14, 2024. The company focuses on developing CAB antibody therapeutics for solid tumor treatment. Management will engage in a fireside chat and investor meetings. This conference provides a platform for BioAtla to showcase its advancements.
BioAtla, Inc. (Nasdaq: BCAB) will host a conference call and webcast on May 14, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and provide business highlights. The company focuses on developing CAB antibody therapeutics for solid tumors.
BioAtla, Inc. (Nasdaq: BCAB) received FDA clearance for its investigational new drug BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for treating various tumors. The CAB technology aims to reduce toxicities, and recent data at the AACR Annual Meeting showcased improved serum stability and potency. BA3361 showed complete tumor regression in cell line xenograft models, superior efficacy in pancreatic cancer, and reduced toxicity. This marks BioAtla's advancement in developing innovative cancer treatments.
FAQ
What is the current stock price of Bioatla (BCAB)?
What is the market cap of Bioatla (BCAB)?
